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Background: Sarcoidosis is a systemic granulomatous disease with unknown etiology.
Objectives: We evaluated seasonal variation, demographic, clinical and diagnostic
features of sarcoidosis in recently diagnosed symptomatic patients in the whole cohort
(275 patients) and in the subgroups according to the estimated disease course (subacute
course group vs. chronic course group). We also developed a prediction model to predict
the course of sarcoidosis using simple clinical and demographic variables.
Material and methods: Two hundred and seventy-five patients with sarcoidosis.
Measurements and statistics: Roger’s test, chi-square, t-test and multiple logistic
regression were used.
Results: The distribution of cumulative monthly diagnosis was the lowest in November
(fall) (po0.01). Seasonal pattern was influenced by age and gender. Constitutional
symptoms, stages 2 and 3 diseases and the absence of erythema nodosum were highly
significant parameters for chronic course. Using these variables, the developed model had
a specificity of 93.1% and its positive predictive value was 89.5%. Progression of the disease
was documented 6.4% in subacute group vs. 32.1% in chronic group (p ¼ 0:00001).
Preventive effect of smoking was more pronounced in females than in males in our cohort.
Conclusions: Further well-designed and large prospective studies are required to better
understand the importance of these findings, and to validate the prediction model
presented here.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Although genetic tendency, environmental factors and
immunologic abnormalities are considered in the pathogen-
esis of sarcoidosis, the exact cause and the pathogenesis of
disease remain unestablished.1,2 In this study, we evaluated
a large cohort of sarcoidosis patients with known date of
onset of symptoms and estimated disease course over a 38
year period followed at a single medical center in Turkey
(1966–2004).
Our aims were to show the seasonal variation, demo-
graphic, clinical and diagnostic features of sarcoidosis and,
then, to develop a clinically useful prediction model to
predict the course of sarcoidosis. We evaluated seasonal
variation, demographic, clinical and diagnostic features of
sarcoidosis in recently diagnosed symptomatic patients in
the whole cohort (275 patients) and in the subgroups
according to the estimated disease course (subacute course
group vs. chronic course group). We also compared these
subgroups with each other. Additionally, we developed a
clinically useful prediction model to predict the course
of sarcoidosis using simple clinical and demographic
variables.
Patients and methods
Study population
We analyzed retrospectively medical records of the Cerrah-
pasa Medical Faculty, Department of Internal Medicine,
Division of Lung Diseases, Istanbul between 1966 and June
2004. In our sarcoidosis clinic, we have used chart review
system since 1964 which was adapted from the Mount Sinai
School of Medicine Sarcoidosis Clinic.
The database contained full records of 492 patients with
sarcoidosis which includes demographic features, presenting
clinical features, initial diagnosis methods and the date and
the age at the initial diagnosis for each patient. All
patients were Turkish origin. Patients with the estimated
disease course (subacute vs. chronic) were selected and
included in this study (the cohort: 275 patients). These
patients are still being followed prospectively according to
the published criteria of WASOG (World Association of
Sarcoidosis and Other Granulomatous Diseases)/ATS (Amer-
ican Thoracic Society)/ERS (European Respiratory Society)
since 1999.2
Definitions and patient selection
Diagnosis of sarcoidosis
For each patient, sarcoidosis was diagnosed by a committee
who were experts on sarcoidosis. This sarcoidosis committee
included one senior sarcoidosis pulmonologist, three other
pulmonologists and one pulmonary radiologist. Additionally,
at the end of every year, the committee was gathered to re-
evaluate all patients with sarcoidosis for progression and
regression assessment.
The diagnosis of sarcoidosis was established when
clinicoradiological findings were supported by histological
evidence of non-caseating epithelioid cell granulomas in one
or more than one organ system and exclusion of otherdisorders known to cause granulomatous disease. Mycobac-
teria and fungus were excluded by tissue stainings and
cultures.
Selection of the patients
We evaluated the pattern of seasonality in the sympto-
matic, recently diagnosed patients with sarcoidosis.
Patients with sarcoidosis diagnosed by chest X-ray
scanning and not symptomatic were excluded. Some
of the patients were diagnosed after Kveim–Siltzbach
test.
Chest radiographs were classified as Scadding described:
stage 0, normal chest radiographic findings; stage 1,
bilateral hilar lymphadenopathy (BHL) alone; stage 2, BHL
with pulmonary infiltrates; stage 3, pulmonary infiltrates
only; stage 4, pulmonary fibrosis/fibrocystic paren-
chymal changes.3 Lo¨fgren’s syndrome was defined as the
association of erythema nodosum with BHL and/or right
paratracheal lymphadenopathy with or without pulmonary
infiltrates.4
We evaluated the pattern of seasonality only in the
symptomatic, recently diagnosed patients with sarcoidosis.
We have also recorded the dates of diagnosis for each
patient. However, we did not use these dates in this study
because the onset of symptomatic presentation of sarcoi-
dosis is more useful than the dates of diagnosis for a
seasonality study.
Distribution of the patients into the subgroups
according to the course of the disease
The diagnostic methods employed in 275 patients were
shown in Table 1. After the selection of patients, the cohort
was divided into two groups by the estimated course of
disease as follows: 115 patients in the subacute course
group (if estimated duration time of disease was less than 2
years) and 160 patients in the chronic course group (if
estimated duration time of disease was more than 2
years).6 Of the 275 patients, seven patients were followed
for 7–18 months, five patients had 18–24 months follow-up,
and the rest of the cohort (263 patients) had more than 24
months follow-up.
The climate features of Turkey and the definition of
seasons
This study was conducted in Istanbul, Turkey, a city with a
continental climate and quite wide temperature differences
between summer and winter.5 Ninety-seven percent of
Turkey lies in Asia and about 3% in Europe. The Asian part
of the country is mainly a long peninsula, bound on the north
by the Black Sea and on the south by the Mediterranean.
Turkey has a relatively high altitude throughout the country.
The Sea of Marmara divides the city into two parts: an Asian
part and a European part. Istanbul is located in the western
part of Turkey and has average temperatures of 42 F (6 1C) in
January and 75 F (24 1C) in July.
The month of presentation was determined as the month
symptoms first appeared. Seasons (quarters) defined in this
study as follows: winter (January–February–March), spring
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Table 1 Initial diagnostic procedures in 275 patients with sarcoidosis.
Number with positive results/total number of biopsies (%)
Subjects with
subacute course
Subjects with chronic
course
Total
# Verified by histology from
Transbronchial 47 (40.9%) 75 (46.9%) 122 (44.4%)
Mediastinoscopy 13 (11.3%) 23 (14.4%) 36 (13.1%)
Scalen lymph node 4 (3.5%) 5 (3.1%) 9 (3.3%)
Peripheral lymph node 9 (7.8%) 15 (9.4%) 24 (8.7%)
Skin 15 (13%) 16 (10%) 31 (11.3%)
Scar-skin 2 (1.7%) 1 (0.6%) 3 (1.1%)
Subcutan nodul 3 (2.6%) 2 (1.3%) 5 (1.8%)
Ocular 0 1 (0.6%) 1 (0.4%)
Parotis 1 (0.9%) 1 (0.6%) 2 (0.7%)
Muscle 0 1 (0.6%) 1 (0.4%)
Pleura 0 2 (1.3%) 2 (0.7%)
Liver 1 (0.9%) 2 (1.3%) 3 (1.1%)
Open lung 0 3 (1.9%) 3 (1.1%)
Nasal ethmoid 1 (0.9%) 2 (1.3%) 3 (1.1%)
Only Kveim 16 (13.9%) 11 (6.9%) 27 (9.8%)a
No histology
BHLþ erythemanodosum 3 (2.6%) 0 3 (1.1%)
Total number 115 160 275
aStatistically significant.
Sarcoidosis 1149(April–May–June), summer (July–August–September) and
fall (October–November–December).Data analysis
The data were presented as mean 7 SD. The monthly
distribution of diagnosis was used to study seasonal variation
by cumulative diagnosis per month during the full 38 year
period. The graphical data presentation was based on the
cumulative monthly averages during the 38 years, expressed
as the percentage above or below the average monthly
value during the entire study period. The amplitude of
seasonal variation was described by the total seasonal
variation. Total seasonal variations were measured as the
sum of the percentage above the average for the month with
the highest value and the percentage below the average for
the month with the lowest value.Statistical methods
Roger’s test for cyclic variation was used to determine the
significance of any seasonal variation of incidence.7 This
statistical analysis determines a simple harmonic cyclic
trend, by dividing a circle into 12 equal sectors and plotting
the monthly frequencies as co-ordinates (x and y) in the
corresponding sectors in the circle. Additionally, t-test and
chi-square test were used. A mathematical model was
developed by multivariate logistic regression test. Prob-
ability (p) values o0.05 were considered as statistically
significant.Results
Demography of the cohort
Initial demographic features were shown in Table 2. Of the
275 patients, 190 (69%) were female, median age of the
cohort was 40.2712.8 year. The majority of patients were in
the third (29.4%) or fourth (24%) decade. The rest of the
cohort was in the fifth (18.5%), second (16%), sixth (8%), and
first (4%) decades, respectively.
Female patients were older than male patients (41.5713.4
year vs. 37.3711 year, respectively, p ¼ 0:008). Erythema
nodosum was more common in female patients than in males
(33.1% vs. 20%, p ¼ 0:013). Female patients were more
common than males in the fifth decade age (22.1% vs.
10.5%, p ¼ 0:01) while male patients were more common than
females in the third decade age (22.6% vs. 44.7%, p ¼ 0:0001).
Demography of the subgroups
Median age of the patients with subacute course was not
different from that of the patients with chronic course.
Median age of female patients in subacute course group was
significantly different from that of the male patients while
median age of female patients in chronic course group was
not different from that of the male patients.
Clinical features in the cohort
Organ involvement was shown in Table 3. Demographic and
clinical features consistent with sarcoidosis did not show any
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Table 3 Organ involvement.
Subjects with
subacute course
Subjects with
chronic course
p-value (subacute
vs. chronic)
Total (275 subjects)
Skin lesions 29 (26.1%) 41 (26.1%) 40.05 70 (26.1%)
Respiratory symptoms 53 (47.7%) 100 (63.7%) ¼ 0.009a 153 (57.1%)
Superficial lymph node
enlargement
19 (17.1%) 31 (19.7%) 40.05 50 (18.7%)
Erythema nodosum 48 (41.7%) 32 (20%) o0.001a 80 (29.1%)
Constitutional symptoms 34 (30.6%) 80 (51%) ¼ 0.001a 114 (42.5%)
Neurologic symptoms 3 (2.7%) 5 (3.2%) 40.05 8 (3%)
Arthralgia/artritis 38 (34.2%) 34 (21.7%) ¼ 0.02a 72 (26.9%)
Ocular involvement 8 (7.2%) 21 (13.4%) 40.05 29 (10.8%)
Hepatomegaly 11 (9.9%) 23 (14.6%) 40.05 34 (12.7%)
Parotis/lacrimal gland
involvement
Par.: 8 (7.2%) Par.: 10 (6.4%) 40.05 Par.: 18 (6.7%)
Lac.: 2 (1.8%) Lac.: 5 (3.2%) 40.05 Lac.:7 (2.6%)
Poliu¨ria 2 (0.9%) 1 (0.6%) 40.05 3 (1.1%)
Splenomegaly 8 (7.2%) 13 (8.3%) 40.05 21 (7.8%)
Myalgia 4 (3.6%) 9 (5.7%) 40.05 13 (4.9%)
PPD anergy 78 (68%) 118 (74%) 40.05 196 (72%)
Three or more than 3 organs
involvement
6 (5.2%) 15 (9.4%) 40.05 21 (7.6%)
Less than 3 organ
involvement
109 (94.8%) 145 (90.6%) 40.05 254 (92.4%)
Hand bone involvementb 3 (2.6%) 6 (5.2%) 9 (3.3%)
Hypercalcemiab 6 (5.2%) 8 (6.9%) 14 (5.1%)
Lupus perniob 1 (0.6%) 6 (5.2%) 7 (2.6%)
Lactation/pregnancyb 6 (5.2%) 0 6 (2.2%)
Heart involvementb 2 (1.2%) 1 (0.6%) 3 (1.1%)
Macroscopic changes on the
fingersb
3 (2.7%) 4 (2.5%) 7 (2.6%)
Lo¨fgren’s syndrome (without
biopsy)b
3 (2.6%) 0 3 (1.1%)
Cancer developmentb 0 2 (1.2%) 2 (0.7%)
aStatistically significant.
bStatistical analysis was not applied for these parameters due to small sample size.
Table 2 Demographic features in 275 patients with sarcoidosis.
Subjects with chronic course p-value (subacute vs. chronic) Total (275 subjects)
Female/male (%)
81/34 109/51 70% vs. 68% 190/85
(70.4%/29.6%) (68.1%/31.9%) p40.05 (69%/31%)
Mean 7 SD for age
~: 40.2712.9 ~: 42.4713.7 39.9711.9 vs. ~: 41.5713.4
#: 38.979.4 #: 36.3711.9 40.3713.5 #: 37.3711.0
p ¼ 0.005a p40.05 p40.05 p ¼ 0.008a
Sarcoidosis in family
3 (2.7%) 5 (3.2%) p40.05 8 (3%)
aStatistically significant.
S.S. Demirkok et al.1150significant difference between patients with subacute vs.
patients with chronic course except respiratory symptoms,
erythema nodosum, constitutional symptoms, arthralgia
and/or arhtritis, and stages 1, 2, and 3 diseases (Tables 2–4).Patients were asked to recall the date of onset of
symptoms of sarcoidosis. The diagnosis of sarcoidosis was
made on the first physician visit in 49.1% of subjects. The
diagnosis of sarcoidosis had been delayed for 2.07773.851
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Sarcoidosis 1151month. Progression was noted in 21.8% of the patients while
remission was noted in 60.4% of the patients within
19.6721.1 month.
Of the 267 patients, 28.5% were smoker (po0.01). There
was a significant difference between female and male
smokers (17.3% vs. 53.7%, po0.01; respectively). There was
no difference between smokers and non-smokers regarding
progression or regression of the disease.Table 5 Monthly percentage variations in 275 sarcoidosis subje
All Female Male Age cat
10–19
Total 275 190 85 11
Percentage 100 69.09 30.909 4
Jan. 21.45 36.84 12.941 100
Feb. 13.45 20 1.176 9.0909
Mar. 13.45 20 1.176 336.36
Apr. 78.91 76.84 83.529 9.0909
May 52.73 38.95 83.529 9.0909
Jun. 39.64 38.95 41.176 118.18
Jul. 25.82 24.21 29.41 100
Aug. 43.27 43.16 43.53 100
Sept. 17.09 24.21 1.176 9.0909
Oct. 4 7.368 29.41 9.0909
Nov. 56.36 43.16 85.88 100
Dec. 30.18 30.53 29.41 100
# Total seasonb 135.3 120 169.41 436.36
Roger’s 0 0.0003 0.002107 0.1063
o0.001c o0.001c o0.01c 40.05
aData points represent cumulative data from 1966 through 2004. S
Percentage above or below the average monthly value.
bSum of the percentage above the average for the month with the h
with the lowest value.
cStatistically significant.
Table 4 Correlation between sarcoidosis patients with
subacute course vs. chronic course.
Subacute
course
Chronic
course
Stage 1a 65 47
Stage 2a 34 72
Stage 3a 5 27
Stage 4 0 2
Skin alone other than EN 6 5
Extrathorasic involvement
other than skin lesions
8 4
aStatistically significant.Male gender, stage 1 disease, constitutional symptoms,
and scalene muscle involvement were more common in the
group age at onset less than 40 years (po0.05) while female
gender, stage 2 disease, and skin involvement were common
in the group age at onset greater than 40 years (po0.05).Seasonal variability in the cohort
Seasonal pattern of the cohort was shown in Table 5. The
distribution of cumulative monthly presentations for the 275
patients showed a significant seasonal variation with Roger’s
test (po0.001). Average monthly presentations differed by
as much as 135.3%, ranging from a peak 78.9% above average
in April (spring) to 56.3% below average in November (fall).
The seasonal pattern of presentations was also influenced by
some age groups and by both genders (po0.001 for female
and po0.01 for male). The amplitude of the seasonal
variation was meaningful among patients 30–39, 40–49, and
50–59 years of age (po0.001, po0.05, and po0.05,
respectively).
A spring peak at the presentations was observed in the
patients by Roger’s test (po0.001). It differed by as much as
87.2%, ranging from a peak 57.1% above average in spring to
30.1% below average in fall. The distribution of presenta-
tions also showed a significant seasonal variation by the firstctsa.
egories
20–29 30–39 40–49 50–59 60–69
44 81 66 51 22
16 29.455 24 18.545 8
9.0909 40.74 45.45 17.647 9.091
18.18 62.963 9.0909 29.41 9.091
18.18 70.37 9.091 88.235 118.2
118.18 107.41 100 41.176 45.45
63.636 62.963 81.818 41.176 45.45
18.18 48.148 81.818 64.706 100
18.18 18.519 100 5.882 9.091
72.73 18.519 81.82 29.41 100
45.45 70.37 9.0909 5.882 118.2
36.364 25.93 9.0909 29.41 9.091
18.18 85.19 27.27 76.47 45.45
18.18 25.93 27.27 76.47 63.64
190.91 192.59 200 164.71 218.2
0.2633 0.000736 0.034715 0.015554 0.3849
40.05 o0.001c o0.05c o0.05c 40.05
easonal variation was shown by all cases, by age and by genders.
ighest value and the percentage below the average for the month
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S.S. Demirkok et al.1152and second half of the year (29.4% vs. 29.4%, po0.001;
respectively). The distribution of cumulative monthly
presentations in the cohort showed a significant seasonal
variation with Roger’s test for all cases in patients with age
at onset less than vs. greater than 40 years, po0.001 and
po0.01, respectively.Patients with subacute course vs. chronic course
The sites of initial diagnostic biopsies, symptoms and signs
were shown in Tables 1, 2 and 3, respectively. The diagnosis
of sarcoidosis was made on the first physician visit in 42.6%
of subjects in subacute vs. in 53.75% of subjects in chronic
(po0.05). The diagnosis of sarcoidosis had been delayed for
2.09172.891 month in the subacute group vs. 2.06774.388
month in the chronic group (p40.05).
Erythema nodosum, stage I disease and arthralgia and/or
arthritis were more common in group with subacute course
than in the group with chronic course (po0.05 for all). On
the contrary, stages II and III diseases, respiratory symp-
toms, constitutional symptoms and 20–29 years of age at the
diagnosis were more commonly seen in group with chronic
course than in the group with subacute course (po0.05 for
all). There were 16 patients (13.9%) in the subacute course
group (vs. 6.8% in chronic course group, p ¼ 0.026)
diagnosed by positive Kveim reaction. There was no
difference regarding other features such as three-organ
involvement, PPD anergy, Kveim reaction results or observed
months. Of the patients, 28.3% in subacute and 28.6% in
chronic course group were smoker (p40.05).
Progression of the disease was noted 6.4% of patients in
subacute group vs. 32.1% in chronic group (p ¼ 0.00001)
while regression was noted 93.6% of the subacute patients
vs. 38.2% in chronics (p ¼ 0.00001).Predictors of severity at the presentation and a
model to predict the course of sarcoidosis
Erythema nodosum, arthralgia and/or arthritis, and stage 1
disease were more observed in the subacute while respira-
tory and constitutional symptoms and stages 2 and 3
diseases were seen more frequently in the chronic groupTable 6 Multivariate logistic regression analysis for all demogr
Sig.
Stage 1 disease
Stage 0 disease 0.132
Stage 2 disease 0.000a
Stage 3 disease 0.001a
ENb positive
Absence of EN 0.036a
Absence of constitutional symptoms
Constitutional symptoms positive 0.016a
aStatistically significant.
bErythema nodosum.by chi-square test (po0.05 for all). These independent
variables by multiple logistic regression test showed only
constitutional symptoms, stages II and III diseases, and the
absence of erythema nodosum which were highly significant
(Table 6). Using these variables, the model (constitutional
symptoms, stage III disease, and the absence of erythema
nodosum combination) has specificity of 93.1% and sensitiv-
ity of 68%. Positive and negative predictive value were 89.5%
and 77.1%, respectively. Diagnostic probability of this model
was 81.5%. Using constitutional symptoms, stage II disease,
and the absence of erythema nodosum, the model has a
specificity of 77.1% and a sensitivity of 67.6%. Positive and
negative predictive value were 67.6% and 77.1%, respec-
tively. Diagnostic probability of this model was 72%. The
combination of erythema nodosum, absence of constitu-
tional symptoms and stage I disease were selected as
reference for these analysis. Positive predictive value of
the last model was 22.9% for chronic course.
Seasonal variation in the group with subacute
course vs. in the group with chronic course
Subacute subgroup: The distribution of cumulative monthly
presentations in the subacute group showed a significant
seasonal variation with Roger’s test (po0.01). Average
monthly presentations differed by as much as 167%, ranging
from a peak 98% above average in April (spring) to 69% below
average in September (summer) (Fig. 1). A spring peak at
the presentations was also observed by Roger’s test
(po0.01). It differed by as much as 104%, ranging from a
peak 67% above average in spring to 37% below average in
summer. The distribution of presentations also showed a
significant seasonal variation by the first and second half of
the year (27% vs. 27%, po0.001; respectively). The
seasonal pattern of presentations was also influenced by
some age groups and by female gender (po0.01). The
amplitude of the seasonal variation was statistically
significant among patients 20–29 and 50–59 years of age
(po0.05 for both). The amplitude of the seasonal variation
was also significant among patients with age at onset less
than 40-year-old (po0.05). Average monthly presentations
differed by as much as 228%, ranging from a peak 169%
above average in April to 59% below average in September.aphic and clinical features.
OR 95% CI–OR
Lower Upper
1
2.158 0.793 5.877
2.887 1.603 5.200
5.562 1.938 15.963
1
1.952 1.045 3.648
1
1.971 1.137 3.417
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Figure 1 Monthly percentage variations in the subgroups
(subacute vs. chronic). The reference value which is the
average monthly value is 0%.
Sarcoidosis 1153This significance was not observed among patients with age
at onset greater than 40.
Chronic subgroup: Presentations for the patients in the
chronic group showed a significant seasonal variation with
Roger’s test (po0.001). Average monthly presentations
differed by as much as 150%, ranging from a peak 80%
above average in April (spring) to 70% below average in
November (fall) (Fig. 1). A spring peak at the presentations
was also observed by Roger’s test (po0.001). It differed by
as much as 92.5%, ranging from a peak 65% above average in
spring to 27.5% below average in both summer and in fall.
The distribution of presentations also showed a significant
seasonal variation by the first and second half of the year
(27% vs. 27%, po0.001; respectively). There was no
difference between the subacute and chronic groups for
the seasonal variations. The seasonal pattern of presenta-
tions was also influenced by one age group (30–39 years of
age, po0.05) and by both genders (po0.05). The amplitude
of the seasonal variation was significant among patients both
less and more than age 40-year-old (po0.05). Average
monthly presentations differed by as much as 154%, ranging
from a peak 100% above average in April to 54% below
average in March, in August, and in November for patients
with age at onset less than 40-year-old. Average monthly
presentations differed by as much as 146%, ranging from a
peak 60% above average in March, in April, and in June to
85% below average in November for patients with age at
onset greater than 40-year-old.Discussion
The World Congress in Kyoto, 1991 defined sarcoidosis as: a
multisystem disorder of unknown cause. Both host and
environmental factors may play important roles on the etio-
pathogenesis of disease.8 Environmental factors are triggers
of the onset of sarcoidosis in genetically susceptible
individuals. In this regard, seasonal variation studies are
important for infective agents and specific time periods.9–15
In this study, we selected symptomatic newly diagnosed
sarcoidosis patients for analysis regarding environmental
risk factors. Additionally and not consistent with previous
reports, we showed the months of the lowest level of
presentation of sarcoidosis. Furthermore, we showed the
influence of both gender and age on the seasonal variation
of sarcoidosis.Our results are consistent with an infectious and/or
contagious etiology as previously reported for Chlamydia
pneumoniae, Propionibacterium acne, Mycobacteria, wood
burning, pine pollen, allergens, farm animals, fine sandy soil
and clay eating.9–15 However, our results further clarified this
issue in favor of sarcoidosis. Observed seasonal variation with
small peak in the winter differed markedly from the seasonal
pattern of acute and chronic bronchitis, pneumonia,
exacerbation of bronchiectasis and other common respira-
tory infections which shows winter predominance.16–18
Additionally, the seasonal pattern of mood changes as
depressive episodes in fall and winter alternate with non-
depressed periods in both spring and summer is on the
opposite side of the seasonal pattern of sarcoidosis reported
in our study although sarcoidosis is associated with an
increased risk of depression.19 Moreover, presenting symp-
toms within the subacute and chronic groups showed a
similar seasonal pattern throughout the year. These findings
lead us to consider similar triggering factors in the etio-
pathogenesis of sarcoidosis subgroups.20
It was reported that sarcoidosis usually presents in adults
younger than 40 years old.2 Our patients were, on the
average, 10 years older than reported series. Genetic and/
or environmental factors or the method of diagnosis might
account for these differences between our patients and
previous series.
A delay in the diagnosis of sarcoidosis might result in
significant unnecessary health-care costs and may affect the
outcome. The ACCESS Research Group have reported that
the diagnosis of sarcoidosis is made on the first physician
visit in only 15.3% of cases (vs. 49.1% in our study group).21
This marked difference between the ACCESS group and our
study mainly results from the patient selection criteria in
these studies. The ACCESS group included all patients with
sarcoidosis while we included only recently diagnosed
patients with symptoms. We proposed that patients pre-
senting with erythema nodosum, arthralgia and/or arthritis
or respiratory complaints during the spring months of the
year could benefit from a more thorough investigation to
rule out sarcoidosis than a similar patient presenting in
either summer or autumn or in that half of the year.
Association between sarcoidosis and smoking was ques-
tioned in this study. The prevalence of smoking in females
and in males was 17.3% and 53.7%, respectively in this study
while the prevalence of smoking was 38–49% in females and
51.5–65% in males in our population. Sarcoidosis appears to
occur more commonly in female non-smokers than in male
non-smokers. We proposed that preventive effect of smok-
ing is more pronounced in females than in males at least in
Turkey. These findings need further clarification.
Biochemical and genetic testing to predict the clinical
course of sarcoidosis has been failed to predict the course so
far. Furthermore, using the most sensitive, least invasive
and expensive tests should be mandatory.22,23 One of the
purposes of this study was to find a simple and clinically
useful model for predicting the course of sarcoidosis. In this
regard, we showed that erythema nodosum, constitutional
symptoms, and stages III and IV diseases can predict the
course of the disease with a high degree of accuracy. Using
these variables, we developed a mathematical model for the
prediction of disease course by multivariate logistic regres-
sion test. Constitutional symptoms, absence of erythema
ARTICLE IN PRESS
S.S. Demirkok et al.1154nodosum and stage II or III disease were the best predictor of
chronicity. The least predictive combination for chronicity
was the absence of constitutional symptoms, erythema
nodosum and stage I disease.
Excellent prognosis features such as stage I disease,
erythema nodosum and acute inflammatory manifestations
were observed more frequently in our patients younger than
40 years. In contrast, stage II disease and skin involvement
which are the features associated with chronic course were
more common in the patients older than 40 years.
Particularly, cancer cases were only seen among chronics.
Further well-designed and large prospective studies are
required to better understand the importance of our findings
and to validate the prediction model.
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